Ulinastatin Reduces Cancer Recurrence after Resection of Hepatic Metastases from Colon Cancer by Inhibiting MMP-9 Activation via the Antifibrinolytic Pathway

<table>Inhibition of ulinastatin on plasmin expression. Horizontal ordinate: (a) control group without reagents; (b) low-dose ulinastatin (L-UTI) group, 800 U/mL ulinastatin; (c) high-dose ulinastatin (H-UTI) group, 8000 U/mL ulinastatin; (d) IL-1<i>α</i> (10 ng/mL) + plasminogen group (10 <i>μ</i>g/mL); (e) IL-1<i>α</i> (10 ng/mL) + plasminogen (10 <i>μ</i>g/mL) + L-UTI group (800 U/mL); (f) IL-1<i>α</i> (10 ng/mL) + plasminogen (10 <i>μ</i>g/mL) + L-UTI group (8000 U/mL). Longitudinal coordinate: plasmin level (pg/mL).</table>

BioMed Research International

fig3

Figure 3

Figure 3: Ulinastatin Reduces Cancer Recurrence after Resection of Hepatic Metastases from Colon Cancer by Inhibiting MMP-9 Activation via the Antifibrinolytic Pathway 

Figure 3 | Ulinastatin Reduces Cancer Recurrence after Resection of Hepatic Metastases from Colon Cancer by Inhibiting MMP-9 Activation via the Antifibrinolytic Pathway 